The European signal first
Two of the clearest data points in this story are European. On 24 July 2026 the EMA's human-medicines committee (CHMP) adopted a positive opinion recommending Gilead's Trodelvy plus Merck's Keytruda for PD-(L)1-positive first-line metastatic triple-negative breast cancer.1 The release says a second first-line approval would establish Trodelvy as a backbone therapy across PD-L1 status in the European Union.1 A CHMP opinion is a recommendation, not a marketing authorisation. The European Commission's decision is the step that matters for patients and budgets, and the dossier does not say when it will come.
Evandro de Azambuja said: "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1."1 He added that a combination approval would build on the recent approval of Trodelvy monotherapy.1
The second signal comes from Novocure, which is registered in Baar, Switzerland. It reported second-quarter 2026 net revenues of $184 million, up 16% year over year, driven by 18% growth in global active patients.2 It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch and more than 280 active patients on the product as of 30 June 2026.2 Frank Leonard called it "our strongest quarter to date, with record net revenues and active patients on therapy."2
What is changing in the pipeline
Our dossier groups three developments under one theme: AI-designed biologics, personalised mRNA vaccines, and antibody-drug-conjugate (ADC) plus bispecific combinations. That grouping is Via News's reading of the material, not an external finding.
Personalised vaccines. Our event record says a personalised vaccine from Merck and Moderna stopped melanoma from returning in what it calls a historic clinical trial.3 Moderna and Merck plan to present detailed results at ESMO on 24 October and to engage with regulators about potential filings.3 Until that data is public, the headline result is a summary and not a dataset. We recommend treating it that way.
ADC and bispecific combinations. Summit Therapeutics announced a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab with Datroway across multiple solid tumour settings, intending to include breast and lung cancer.3 Separately, Summit's Biologics License Application for ivonescimab, based on the HARMONi trial, has an FDA action date of 14 November 2026.3 Those are two different events. The first is a plan to test a combination, and the second is a regulatory decision on the single drug.
Radiopharmaceuticals. Telix, listed in Australia and the US, dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma.4 The company describes it as the first radiopharmaceutical therapy to enter Phase 3 for this cancer.4 Aviral Singh said outcomes "remain poor for many patients."4
AI in drug design: what is claimed, and how reliable the source is
AstraZeneca's 'lab of the future' is described in an MIT Technology Review piece. Puja Sapra says: "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."5 She names data as the differentiator: "Data is our differentiator."5
The article is also candid about limits. "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."5 And: "With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients."5 For multi-specific biologics, she says such models could help choose "which two or three targets to prioritize" and balance potency, stability, manufacturability and safety.5
Our reliability check matters here. Of 11 claims we checked from that article, none held up against our verification standard.5 That does not mean the claims are false. These are forward-looking statements and descriptions of capability, which are hard to test against a record. It does mean that nothing in the dossier shows AI-designed molecules reaching patients. This is a statement of intent from a large company, not a result. European readers should note that none of the dossier's AI material addresses EU rules.
Merck's checked numbers: big spending, thinner cash
Merck sits at the centre of both the vaccine and the Keytruda stories, and its SEC-filed figures are the one part of this piece we can state as verified. Capital expenditure was $3.863 billion in fiscal 2023, $3.372 billion in 2024 and $4.112 billion in 2025.6 To size the last figure, the 2025 outlay is about 22 times Novocure's entire quarterly revenue of $184 million.2,6
Cash tells a less steady story. Year-end cash was $6.841 billion in 2023, $13.242 billion in 2024 and $14.565 billion in 2025.6 It peaked at $18.169 billion in the third quarter of 2025.6 At the end of the second quarter of 2026 it was $6.849 billion, down from $8.007 billion a year earlier.6
Cost of revenue is also rising. It was $4.395 billion in the second quarter of 2026 against $3.557 billion in the second quarter of 2025, an increase of about 24% by our arithmetic.6 First-quarter cost of revenue rose from $3.419 billion to $4.195 billion, about 23%.6 The filings do not say why, and we will not guess. Many index funds hold large pharmaceutical groups, but the dossier gives no fund weightings, so we cannot say how much any reader owns.
The smaller names are more mixed
Our narrative notes that Q2 oncology guidance was narrowed and raised, that Kiniksa's Arcalyst revenue grew, and that OPKO issued softer Q3 guidance. The dossier has no figures for these, so we do not give any.
ADC Therapeutics shows the pressure on smaller companies more concretely. It is cutting jobs, which it says is "projected to deliver $10 million in annualised cost savings."7 It says it "maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations."7 This comes from a weekly sector round-up, which our checks put at 45% of 520 claims held up, so it is a company statement relayed by a secondary source.7
A note on source quality
The two press-release sources behind the Novocure and CHMP items held up on 56% of 4,956 checked claims.1,2 The Telix source held up on 31% of 2,927.4 Company releases report what companies choose to say. The Merck SEC figures are the exception, because they are filed data.
What to watch
- 24 October: the detailed intismeran data at ESMO, and whether Merck and Moderna say anything concrete about filing plans.3
- 14 November: the FDA action date for ivonescimab.3
- The European Commission's decision on Trodelvy plus Keytruda following the CHMP opinion.1
- Optune Pax in Germany: whether the 280-plus patient base grows after the first EU launch.2
- Merck's next filing: whether cash stays near $6.8 billion while cost of revenue keeps rising.6
